Activating Nrf2 mutations are common in lung squamous carcinomas (6.2%; 71/1144) but are infrequent in lung adenocarcinomas (1.9%; 17/915), where Nrf2 activating driver mutations are only ~60% (17/915) of these mutations. This evidence concerns the gene NFE2L2 and lung adenocarcinoma.